1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBioTools Innovator VANGUARD Enabling Technologies Hub Proof-of-Concept Funding is sponsored by BARDA DRIVe. BioTools Innovator VANGUARD Enabling Technologies Hub Proof-of-Concept Funding is a grant from BARDA DRIVe that funds small businesses developing enabling life science technologies for drug discovery, biomanufacturing, and bioanalytic and diagnostic instrumentation.
Get alerted about grants like this
Save a search for “BARDA DRIVe” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Leading accelerator program for life science enabling technologies. Enabling Technologies Hub BARDA Accelerator Network Enabling the Development of Innovations in Drug Discovery and Development, Biomanufacturing, and Bioanalytic and Diagnostic Instrumentation to Improve Clinical Research and Response BioTools Innovator VANGUARD is at the forefront of innovation for enabling life science technologies.
VANGUARD supports biotools startups to develop solutions that improve drug discovery and development; to increase biomanufacturing speed, capacity, portability, and scalability; to enhance sample processing efficiency and diagnostic assay capabilities; and to accelerate bioanalysis of emerging pathogens.
VANGUARD stands ready to support startups in deploying innovative medical countermeasures that enhance the United States’ readiness for public health emergencies.
VANGUARD is a joint initiative between BioTools Innovator, the world’s first-ever accelerator focused on life science research tools, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
BioTools Innovator VANGUARD Opportunities BioTools Innovator VANGUARD consists of two programs, a health security-focused accelerator track as part of the core BioTools Innovator annual cohort, and a specialized technical development, evaluation, and validation non-dilutive funding opportunity. Companies may apply to either or both programs.
BioTools Accelerator Program Track The BioTools Innovator VANGUARD Accelerator will select up to 10 companies annually to participate in a specialized track of the BioTools Innovator accelerator, a four-month program.
Non-Dilutive Funding Program BioTools VANGUARD provides non-dilutive funding to support the Development, Evaluation, and Validation program for technologies that advance BARDA’s mission to enhance pandemic preparedness and health security.
Through Level UP-XR: Training for Biopharmaceutical Manufacturing Technicians, BioTools Innovator VANGUARD will provide non-dilutive funding to innovative CDMO and XR companies creating next-generation training solutions that strengthen the biopharmaceutical manufacturing workforce. Congratulations to our 2025 VANGUARD Cohort!
The BARDA Accelerator Network In Partnership with the Biomedical Advanced Research and Development Authority The BARDA Accelerator Network aims to provide comprehensive support to health security innovators, startups and BARDA portfolio companies through wrap-around accelerator services, technical and business/commercialization expertise, and resources.
The network will facilitate the rapid development, evaluation, validation and commercialization of medical countermeasures. Learn more at the BARDA Accelerator Network . BARDA Accelerator Network Hubs The BARDA Accelerator Network, made up of five Hubs, is built to drive growth in the startup ecosystem by speeding up the creation and market entry of cutting-edge health security solutions.
Each Hub sources promising early-stage innovations within their specialized technology areas and offers funding to evaluate the feasibility of these concepts and provides resources for commercialization, helping to fast-track product development and validation.
BioTools Innovator VANGUARD is at the forefront of biomanufacturing innovation, enabling life science tools startups to develop solutions that improve drug discovery and development; increase speed, capacity, portability, and scalability; and improve clinical research and clinical care coordination.
Diagnostics & Medical Devices The International Consortium for Research, Engineering, Acceleration of Technology Excellence (I-CREATE) Hub supports the development and acceleration of novel diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.
Focus on innovations that can improve the detection, diagnosis, treatment, and informed outcomes in pediatric/neonatal populations and immunocompromised populations to enable health equity solutions in traditionally underrepresented communities and low-resource settings.
Therapeutics and Vaccines The Vaccine Innovations and Therapeutics Acceleration Launchpad (VITAL) Hub will support the development and acceleration of next-generation therapeutic and vaccine platforms and technologies. Focus on the development and application of digital health tools to empower people to prepare for and respond to health security threats and improve the continuum of clinical care.
BioTools Innovator VANGUARD is at the forefront of biomanufacturing innovation, enabling life science tools startups to develop solutions that improve drug discovery and development; increase speed, capacity, portability, and scalability; and improve clinical research and clinical care coordination.
Diagnostics & Medical Devices The International Consortium for Research, Engineering, Acceleration of Technology Excellence (I-CREATE) Hub supports the development and acceleration of novel diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.
Focus on the development and application of digital health tools to empower people to prepare for and respond to health security threats and improve the continuum of clinical care.
Focus on innovations that can improve the detection, diagnosis, treatment, and informed outcomes in pediatric/neonatal populations and immunocompromised populations to enable health equity solutions in traditionally underrepresented communities and low-resource settings.
Therapeutics and Vaccines The Vaccine Innovations and Therapeutics Acceleration Launchpad (VITAL) Hub will support the development and acceleration of next-generation therapeutic and vaccine platforms and technologies. For additional information and questions, please contact vanguard@biotoolsinnovator. org .
Based on current listing details, eligibility includes: Small businesses developing technologies for health security. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $50,000-$200,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.